New hope for advanced breast cancer patients after chemotherapy fails

NCT ID NCT04489173

Completed Disease control Sponsor: Borstkanker Onderzoek Groep Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a chemotherapy drug called trifluridine/tipiracil in 52 women with advanced ER-positive, HER2-negative breast cancer that had already been treated with other chemotherapies. The goal was to see if the drug could slow cancer growth and improve quality of life. The study is complete, and results will show how well the drug works and what side effects occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm chemotherapy-induced toxicity hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM CHEMOTHERAPY EFFECT

Contacts and locations

Locations

Amphia Ziekenhuis

Breda, Netherlands
Catharina Ziekenhuis

Eindhoven, Netherlands
Deventer ziekenhuis

Deventer, Netherlands
Erasmus MC

Rotterdam, Netherlands
MC Leeuwarden

Leeuwarden, Netherlands
MUMC

Maastricht, Netherlands
Reinier de Graaf Groep

Delft, Netherlands
Rijnstate

Arnhem, Netherlands
UMC Utrecht

Utrecht, Netherlands
Wilhelmina ziekenhuis

Assen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.